BioSpace News Archive

Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the first quarter ended March 31, 2022 and provided a clinical update on its Phase 3 clinical program of simufilam in Alzheimer’s disease.

Turning Point Therapeutics, Inc. (NASDAQ: TPTX), announced today that it has entered into an exclusive license agreement with LaNova Medicines Limited (LaNova) to develop and commercialize LM-302, a novel antibody drug conjugate (ADC) targeting Claudin18.2, in the U.S. and rest of the world, excluding Greater China and South Korea.

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced financial results for its first quarter 2022.

Surgalign Holdings, Inc. today announced that the Company’s HOLO Portal surgical guidance system has officially entered clinical use.

Centene Corporation announced that it has signed a definitive agreement to sell Magellan Rx to Prime Therapeutics LLC and a separate definitive agreement to sell PANTHERx Rare to a consortium of The Vistria Group, General Atlantic, and Nautic Partners.

Daewoong Pharmaceutical announced its financial results for the first quarter of 2022.

Evofem Biosciences, Inc., announced that the Board and stockholders of the Company approved a 1-for-15 reverse stock split of the Company’s common stock at the annual meeting of the Company held on May 4, 2022.

Pharmacy benefit manager Prime Therapeutics LLC (Prime) on May 3 entered into a definitive agreement with Centene Corporation to acquire Magellan Health, Inc.'s pharmacy business, Magellan Rx Management, (Magellan Rx) for approximately $1.35 billion.

In 2020, 3.7% of U.S. adults currently used electronic nicotine delivery systems 1 with 18.5% of users reporting gingival pain and or oral bleeding2 making this a concerning human health threat.

Medidata , a Dassault Systèmes company, announced that Ergomed’s Rare Disease Innovation Center TM will leverage Medidata’s Patient Cloud, Intelligent Trials technologies, and Synthetic Control Arm Ⓡ to help sponsors reduce clinical trial timelines, optimize patient experiences, and bring effective rare disease therapies to market more quickly.